Researchers Submit Patent Application, "Lentiviral Vectors Enabling Routing Antigens To Mhc-Ii Pathway And Inducing Cd4+ And Cd8+ T-Cell Responses In A Host", for Approval (USPTO 20230364216).
In: Vaccine Weekly, 2023-12-08, S. 191-191
serialPeriodical
Zugriff:
This document is a patent application for a new vaccine technology called Lentiviral Vectors (LV). The technology aims to enhance the immune response by inducing both CD4+ and CD8+ T-cell responses. It utilizes a recombinant lentiviral vector genome that encodes a fusion polypeptide consisting of a multimerization scaffold and an antigenic polypeptide, as well as a CD40L ectodomain. The patent application also includes a method for preparing the lentiviral vector particles and a pharmaceutical composition for use in vaccination. The inventors of this technology are Francois Anna, Catherine Blanc, Pierre Charneau, Jodie Lopez, Laleh Majlessi, and Fanny Moncoq. This technology has the potential to improve the effectiveness of vaccines by maximizing the immune response. [Extracted from the article]
Copyright of Vaccine Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Lentiviral Vectors Enabling Routing Antigens To Mhc-Ii Pathway And Inducing Cd4+ And Cd8+ T-Cell Responses In A Host", for Approval (USPTO 20230364216).
|
---|---|
Zeitschrift: | Vaccine Weekly, 2023-12-08, S. 191-191 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1074-2921 (print) |
Schlagwort: |
|
Sonstiges: |
|